MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Mersana Therapeutics EPS Ratio 2011-2026 | MRSN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Mersana Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.56 | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 | -2.79 | -3.22 | -10.8 | -13.4 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.56 | -13.4 | -3.9 |
Quarterly EPS Ratio Mersana Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.51 | -4.87 | -0.19 | - | -2.34 | -4.96 | -0.16 | - | -0.35 | -0.47 | -0.52 | - | -0.61 | -0.55 | -0.59 | - | -0.63 | -0.59 | -0.5 | -0.42 | -0.33 | -0.33 | -0.35 | -0.34 | -0.35 | -0.36 | 0.72 | 0.97 | -0.74 | -0.54 | -0.54 | 0.61 | -0.35 | -6.33 | -6.02 | 0.07 | -4.56 | -3 | -4.31 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.97 | -6.33 | -1.3 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-13.1 | $ 9.33 | 1.41 % | $ 603 M |  USA |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-0.19 | $ 0.87 | -2.13 % | $ 6.4 M | China |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 22.38 | 0.81 % | $ 3.71 B | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
-1.58 | $ 28.15 | 1.04 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
0.28 | $ 8.22 | 3.92 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
2.76 | $ 30.95 | -0.34 % | $ 1.78 B | USA |
 |
ImmuCell Corporation
ICCC
|
-0.12 | $ 8.43 | -0.12 % | $ 76.1 M | USA |
 |
InflaRx N.V.
IFRX
|
-1.26 | $ 1.97 | -0.51 % | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
6.59 | $ 98.55 | -0.55 % | $ 19.2 B | USA |
 |
InMed Pharmaceuticals
INM
|
-3.25 | $ 0.71 | 1.27 % | $ 1.74 M |  Canada |
 |
Innoviva
INVA
|
4.02 | $ 22.97 | -0.35 % | $ 1.55 B | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 104.02 | 2.41 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
-23 | $ 7.34 | -6.79 % | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-2.03 | $ 26.68 | 0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-0.66 | $ 1.45 | -2.68 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
-0.05 | $ 8.16 | 0.68 % | $ 260 M |  Israel |
 |
Krystal Biotech
KRYS
|
7.08 | $ 260.24 | 0.11 % | $ 7.53 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-0.186 | $ 13.58 | 9.34 % | $ 1.8 B |  Australia |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.22 | $ 220.06 | -2.13 % | $ 4.02 B | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.94 | -1.67 % | $ 4.84 M | Israel |
 |
Liquidia Corporation
LQDA
|
-0.8 | $ 38.41 | 0.67 % | $ 3.31 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.08 | 0.62 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.15 | 3.49 % | $ 2.95 B | USA |